Business · 28/09/2018Updated: 10/17/2026 · 1 min read
GlaxoSmithKline, LLC, et al.; Withdrawal of Approval of 24 Abbreviated New Drug Applications
Summary
The US Food and Drug Administration (FDA) is withdrawing approval of 24 abbreviated new drug applications (ANDAs) from multiple applicants, following written notifications that the drug products are no longer commercially available.